Cellectar Biosciences, Inc. (CLRB)
Market Cap | 48.91M |
Revenue (ttm) | n/a |
Net Income (ttm) | -37.98M |
Shares Out | 12.29M |
EPS (ttm) | -3.11 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,761,846 |
Open | 3.840 |
Previous Close | 3.635 |
Day's Range | 3.790 - 4.070 |
52-Week Range | 1.300 - 4.450 |
Beta | 0.93 |
Analysts | Strong Buy |
Price Target | 20.00 (+402.51%) |
Earnings Date | Mar 27, 2024 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CLRB stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 402.51% from the latest price.
News
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial...
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial...
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial...
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercia...
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerciali...
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI) Study of Iopofosine I 131 Supported by $2 Million Grant from the Nationa...
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient
Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies Io...
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16...
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.
Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia Dr. Levy to Provide Perspective on Iopofosine I 131's Pot...
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy Partnership to Provide Key Data on WM Treatment Landscape a...
Cellectar's blood cancer therapy succeeds in trial
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines...
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia
FLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads Expanded Global Patent Provides Protection for Phospho...
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWI...
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia
The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options The EMA's PRIME status is gran...
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerciali...
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
Interim data from 64 refractory multiple myeloma patients demonstrated an ORR of 28%, a CBR of 70%, and a DCR of 92%
Cellectar Provides a Research and Development Program Summary
Waldenstrom's macroglobulinemia pivotal trial top-line data now expected second half of 2023; pediatric high-grade glioma trial to initiate in Q3
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of t...